Clinical Trial Update: AMG 595 First-in-Human in Recurrent Gliomas [Phase 1]

View source ↗

Summary

Amgen completed a first-in-human Phase 1 trial of AMG 595 in recurrent gliomas to assess safety and early signals of activity. The study included malignant glio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma Multiforme
• Malignant Glioma

Drugs mentioned

• AMG 595

Snippet

Sponsor: Amgen | Conditions: Advanced Malignant Glioma, Anaplastic Astrocytomas | Phase 1 | Status: COMPLETED